癌变·畸变·突变

• 论著 • 上一篇    下一篇

-单克隆抗体对人卵巢癌细胞株OC-3-VGH裸鼠皮下移植瘤的抑制作用

谢琛静,刘向云,桂  博,崇立明,许  丽,潘  琦,周  莉,孙祖越*   

  1. ( 上海市计划生育科学研究所药理毒理学研究室,中国生育调节药物毒理检测中心,上海 200032 )
  • 收稿日期:2012-09-19 修回日期:2012-10-11 出版日期:2013-01-30 发布日期:2013-01-30
  • 通讯作者: 孙祖越
  • 作者简介:谢琛静 (1982- ),女,助理研究员,研究方向:生殖药理毒理学。E-mail:xiecj417@163.com
  • 基金资助:

    国家“重大新药创制”科技重大专项 (2011ZX09301-005);上海市“科技创新行动计划”项目 (11140901300; 11140901302)

Inhibitory effect of 131I-monoclonal antibody on subcutaneously transplanted human ovarian cancer cell line OC-3-VGH tumor

XIE Chen-jing,LIU Xiang-yun,GUI Bo,CHONG Li-ming,XU Li,PAN Qi,ZHOU Li,SUN Zu-yue*   

  1. (Department of Pharmacology and Toxicology, Shanghai Institute of Planned Parenthood Research, National Evaluation Centre for the Toxicology of Fertility Regulating Drugs, Shanghai 200032, China)
  • Received:2012-09-19 Revised:2012-10-11 Online:2013-01-30 Published:2013-01-30
  • Contact: SUN Zu-yue,E-mail:sunzy64@163.com

摘要:

目的: 探索131I-单克隆抗体对人OC-3-VGH卵巢癌裸鼠肿瘤的抑制作用。方法:建立人卵巢癌裸鼠皮下移植瘤模型,将28只移植瘤模型裸鼠随机分成7组,即阴性对照组 (等体积生理盐水)、60 mg/kg环磷酰胺 (cyclophosphamide,CP)阳性组、单抗高 (10 mg/kg)、低 (2 mg/kg)剂量组、131I-单抗高剂量组 (10 mg/kg+125 μCi)、131I-单抗中剂量组 (6 mg/kg+75 μCi)、131I-单抗低剂量组 (2 mg/kg+25 μCi),各组连续腹腔给药14 d,分别在第0天 (d0)、d4、d8、d12、d15称量裸鼠体质量,测量肿瘤体积,于末次给药后24 h,剖瘤称取质量,计算相对肿瘤增殖率和抑瘤率。结果:与阴性对照组相比,单抗高剂量组、131I-单抗中、高剂量组均显著抑制肿瘤生长,相对肿瘤增殖率分别是54%、48%、30%,抑瘤率分别为33.59%、45.80%、64.89%,差异均具有统计学意义 (P<0.01),单抗高剂量组与131I-单抗高剂量组间的差异也具有统计学意义 (P<0.05)。结论:单克隆抗体和131I-单克隆抗体对人OC-3-VGH卵巢癌均有明显的抑制作用,131I-单克隆抗体高剂量组有明显的增效作用。

关键词: 裸鼠, 卵巢癌, 移植瘤, 抑瘤率, 放射免疫疗法

Abstract:

OBJECTIVE: To explore the inhibitory effect of 131I-monoclonal antibody on tumor growth of human ovarian cancer cell line OC-3-VGH in nude mice. METHODSThe transplanted human ovarian carcinoma model was established by subcutaneous injection of OC-3-VGH cells in nude mice. The mice were randomly divided into negative control group,CP positive control group (60 mg/kg),high dose (10 mg/kg),low dose (2 mg/kg) group of monoclonal antibody,high dose (10 mg/kg+125 μCi),medium dose (6 mg/kg+75 μCi),low dose (2 mg/kg+25 μCi) group of 131I- monoclonal antibody. Seven groups received continuously intraperitoneal injection for 14 d. Diameters of tumors were measured and nude mice were weighed on d0,d4,d8,d12,d15. The animals were killed 24 h after the last treatment. The transplanted tumors were weighed,the inhibitory rate and treatment over control growth ratios were calculated. RESULTS:The high dose monoclonal antibody group,and medium and high dose 131I-monoclonal antibody groups had significant tumor inhibiting effects in vivo,with treatment over control growth ratios of 54%,48%,30% and inhibitory rates of 33.59%,45.80% and 64.89%,respectively. Compared with the negative control,there was significant difference(P<0.01) . The high dose monoclonal antibody group was compared with the high dose 131I-monoclonal antibody group,showing a statistical difference (P<0.05). CONCLUSION: Both monoclonal antibody and 131I- monoclonal antibody groups effectively inhibited the growth of human ovarian carcinoma in vivo. The therapeutic efficiency was enhanced significantly in the high dose 131I-monoclonal antibody group.

Key words: nude mice, ovarian cancer, transplanted tumor, tumor inhibitory rate, radioimmunotherapy